Observational Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4666-4672
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4666
Figure 1
Figure 1 IgG anti-Epstein-Barr virus according to clinical scenarios in Crohn’s disease patients and healthy controls. New patient (n = 13), remission (n = 13), active disease (n = 10) and control (n = 36). P < 0.05 for new patient vs remission and controls. Values are expressed as mean ± SD.
Figure 2
Figure 2 Relationship between anti-Epstein-Barr virus IgG and B cells according to treatment in Crohn’s disease patients. Patients treated with 5-aminosalicylic acid (5-ASA) were significantly different from untreated patients (No) (Ps < 0.05). Values are expressed as mean ± SD.
Figure 3
Figure 3 Anti-Epstein-Barr virus IgG according to tonsillectomy in Crohn’s disease patients and controls. Tonsillectomized patients had significantly higher values; P < 0.05 for CD patients and all subjects. Values are expressed as mean ± SD. EBV: Epstein-Barr virus; CD: Crohn’s disease.